- • Up to 20% off your first purchase
- • Bulk quantities available
- • Citation Reward application
Sample Application
- Animal health test
- In-vitro diagnostics
- Food & Feed Safety
- Environmental Safety
- New drug discovery
Supports
- Talk to our Expert:
[email protected] -
Talk to our sales:
[email protected]
Protocol Library Download
 |
 |
Anti-TNNI3 monoclonal antibody
Pre-made anti-TNNI3 monoclonal antibody(mab)-benchmark antibody for ELISA, affinity binding assay, drug discovery and mechanism of action (MOA) research
Go to TNNI3/TNNI3 products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)
MSDSProduct information
| Catalog No. | Product Name | Species Reactivity |
|---|---|---|
| GM-Tg-hg-T20186-Ab-1/ GM-Tg-hg-T20186-Ab-2 | Anti-Human TNNI3 monoclonal antibody | Human |
| GM-Tg-rg-T20186-Ab-1/ GM-Tg-rg-T20186-Ab-2 | Anti-Rat TNNI3 monoclonal antibody | Rat |
| GM-Tg-mg-T20186-Ab-1/ GM-Tg-mg-T20186-Ab-2 | Anti-Mouse TNNI3 monoclonal antibody | Mouse |
| GM-Tg-cynog-T20186-Ab-1/ GM-Tg-cynog-T20186-Ab-2 | Anti-Cynomolgus/ Rhesus macaque TNNI3 monoclonal antibody | Cynomolgus/ Rhesus macaque |
| GM-Tg-felg-T20186-Ab-1/ GM-Tg-felg-T20186-Ab-2 | Anti-Feline TNNI3 monoclonal antibody | Feline |
| GM-Tg-cang-T20186-Ab-1/ GM-Tg-cang-T20186-Ab-2 | Anti-Canine TNNI3 monoclonal antibody | Canine |
| GM-Tg-bovg-T20186-Ab-1/ GM-Tg-bovg-T20186-Ab-2 | Anti-Bovine TNNI3 monoclonal antibody | Bovine |
| GM-Tg-equg-T20186-Ab-1/ GM-Tg-equg-T20186-Ab-2 | Anti-Equine TNNI3 monoclonal antibody | Equine |
Size： 1mg | 10mg | 100mg
Product Description
| Catalog No. | GM-Tg-hg-T20186-Ab-1/ GM-Tg-hg-T20186-Ab-2; GM-Tg-rg-T20186-Ab-1/ GM-Tg-rg-T20186-Ab-2; GM-Tg-mg-T20186-Ab-1/ GM-Tg-mg-T20186-Ab-2; GM-Tg-cynog-T20186-Ab-1/ GM-Tg-cynog-T20186-Ab-2; GM-Tg-felg-T20186-Ab-1/ GM-Tg-felg-T20186-Ab-2; GM-Tg-cang-T20186-Ab-1/ GM-Tg-cang-T20186-Ab-2; GM-Tg-bovg-T20186-Ab-1/ GM-Tg-bovg-T20186-Ab-2; GM-Tg-equg-T20186-Ab-1/ GM-Tg-equg-T20186-Ab-2 |
| Products Name | Anti-TNNI3 monoclonal antibody |
| Format | mab |
| Target Name | TNNI3 |
| Protein Sub-location | Introcelluar Protein |
| Category of antibody | Therapeutics Target antibody, Diagnostic target antibody |
| Derivation (species) | Mouse |
| CH1+2+3 Isotype (Receptor identification) | IgG |
| Type of Light Chain (VD-LC) | N/A |
| Expression platform | Mammalian Expression |
| Bioactivity validation | Binding affinity is validated by ELISA with recombinant soluble protein antigen. The potency in neutralizing, inhibiting or blocking of the target protein is not detected. |
| Tag | Fc |
| Products description | Pre-made anti-TNNI3 monoclonal antibody(mab) is expressed by mammalian cell line as a benchmark antibody for cell culture, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) |
| Purity | Purity: ≥95% (SDS-PAGE) |
| Application | Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research. |
| Formulation | Lyophilized from sterile PBS, PH 7.4 |
| Storage | Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles. |
Reference
Data / case study
Click to get more Data / Case study about the product.
Associated products
| Category | Cat No. | Products Name |
| Target Antigen | GM-Tg-g-T20186-Ag-1 | Recombinant multi-species TNNI3/ CMD1FF/ CMD2A protein |
| ORF Viral Vector | pGMLP002894 | human TNNI3 Lentivirus plasmid |
| ORF Viral Vector | vGMLP002894 | human TNNI3 Lentivirus particle |
| ORF Viral Vector | pGMLPm001568 | mouse Tnni3 Lentivirus plasmid |
| ORF Viral Vector | vGMLPm001568 | mouse Tnni3 Lentivirus particle |
Target information
| Target ID | GM-T20186 |
| Target Name | TNNI3 |
| Gene ID | 7137,21954,29248,698470,403566,493744,511094,100034065 |
| Gene Symbol and Synonyms | CMD1FF,CMD2A,CMH7,cTnI,RCM1,Tn1,TnI,TNNC1,TNNI3 |
| Uniprot Accession | P19429,P23693,Q8MKD5,Q863B6,P08057,Q5PYI0 |
| Uniprot Entry Name | TNNI3_HUMAN,TNNI3_RAT,TNNI3_FELCA,TNNI3_CANLF,TNNI3_BOVIN,TNNI3_HORSE |
| Protein Sub-location | Introcelluar Protein |
| Category | Therapeutics Target, Diagnostics Biomarker |
| Disease | N/A |
| Gene Ensembl | ENSG00000129991 |
| Target Classification | N/A |
The target: TNNI3, gene name: TNNI3, also named as CMD1FF, CMD2A, CMH7, RCM1, TNNC1, cTnI. Troponin I (TnI), along with troponin T (TnT) and troponin C (TnC), is one of 3 subunits that form the troponin complex of the thin filaments of striated muscle. TnI is the inhibitory subunit; blocking actin-myosin interactions and thereby mediating striated muscle relaxation. The TnI subfamily contains three genes: TnI-skeletal-fast-twitch, TnI-skeletal-slow-twitch, and TnI-cardiac. This gene encodes the TnI-cardiac protein and is exclusively expressed in cardiac muscle tissues. Mutations in this gene cause familial hypertrophic cardiomyopathy type 7 (CMH7) and familial restrictive cardiomyopathy (RCM). Troponin I is useful in making a diagnosis of heart failure, and of ischemic heart disease. An elevated level of troponin is also now used as indicator of acute myocardial injury in patients hospitalized with moderate/severe Coronavirus Disease 2019 (COVID-19). Such elevation has also been associated with higher risk of mortality in cardiovascular disease patients hospitalized due to COVID-19. [provided by RefSeq, Aug 2020].
About Gmab
GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.
Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.
Facebook
LinkedIn
Twitter
